Litigation Details for Novo Nordisk, Inc. v. Viatris Inc. (N.D.W. Va. 2023)

Novo Nordisk, Inc. v. Viatris Inc. (N.D.W. Va. 2023)

Docket		Date Filed	2023-01-27
Court	District Court, N.D. West Virginia	Date Terminated	2023-11-01
Cause	35:271 Patent Infringement	Assigned To	Thomas Shawn Kleeh
Jury Demand	None	Referred To
Patents	10,888,605; 11,318,191; 8,129,343; 8,536,122; 9,764,003
Link to Docket	External link to docket

Details for Novo Nordisk, Inc. v. Viatris Inc. (N.D.W. Va. 2023)

Date Filed	Document No.	Description	Snippet	Link To Document
2023-01-27				External link to document

Novo Nordisk v. Viatris, 1:23-cv-00013: Litigation Summary and Patent Analysis

Last updated: September 6, 2026

Novo Nordisk Inc. v. Viatris Inc., No. 1:23-cv-00013, is a Hatch-Waxman patent case concerning Viatris’ proposed generic liraglutide injection, the active pharmaceutical ingredient in Novo Nordisk’s Victoza product. Novo Nordisk filed the action in the U.S. District Court for the District of Delaware after receiving Viatris’ Paragraph IV notice concerning an abbreviated new drug application, or ANDA. The dispute implicates Novo Nordisk’s Orange Book-listed patents covering liraglutide and related pharmaceutical uses.

The case presents a conventional generic-entry challenge: Viatris seeks FDA approval before the full commercial and patent life of Victoza has ended, while Novo Nordisk seeks an order preventing FDA approval or commercial launch until the asserted patents expire or the litigation is resolved.

What drug is at issue in Novo Nordisk v. Viatris?

The litigation concerns liraglutide injection, a glucagon-like peptide-1, or GLP-1, receptor agonist marketed by Novo Nordisk as Victoza.

Item	Information
Reference-listed drug	Victoza
Active ingredient	Liraglutide
Dosage form	Subcutaneous injection
Therapeutic class	GLP-1 receptor agonist
Primary approved use	Type 2 diabetes
Plaintiff	Novo Nordisk Inc.
Defendant	Viatris Inc.
Court	U.S. District Court for the District of Delaware
Case number	1:23-cv-00013
Case type	Hatch-Waxman ANDA patent litigation
Regulatory trigger	Viatris Paragraph IV certification

Victoza is distinct from Ozempic and Wegovy. Ozempic and Wegovy contain semaglutide, while Victoza and Saxenda contain liraglutide. The case therefore does not directly determine generic entry for Novo Nordisk’s semaglutide franchise.

What patents protect Victoza and liraglutide injection?

Novo Nordisk’s Victoza patent estate has included compound, formulation, and method-of-use patents. The asserted patents in an ANDA case are determined by the patents identified in the complaint and the Paragraph IV notice, rather than by every patent historically associated with the product.

The relevant protection categories are:

Liraglutide compound patents

The foundational liraglutide patents protect the modified GLP-1 molecule and related acylated GLP-1 compounds. These patents established the principal exclusivity platform for Victoza and related liraglutide products.

The earliest compound protection has expired or reached the end of its enforceable term in the United States. Later patents and pediatric exclusivity can extend commercial protection beyond the expiration of the foundational patent.

Formulation and delivery patents

Later patents may cover:

• Liraglutide formulations suitable for injection
• Concentration and excipient combinations
• Stability characteristics
• Multidose pen delivery systems
• Cartridge or injector configurations
• Manufacturing methods for the drug product

Formulation patents can create a separate barrier to generic launch even after a compound patent expires. A generic applicant may attempt to design around those patents or certify that they are invalid, unenforceable or not infringed.

Method-of-use patents

Novo Nordisk has also obtained patents directed to therapeutic uses of liraglutide, including treatment of type 2 diabetes, glycemic control and related metabolic conditions. Method-of-use patents are particularly relevant when an ANDA applicant uses a section viii statement to carve out a patented indication from its proposed label.

A skinny-label strategy can reduce infringement exposure, but it does not eliminate risk if the generic product is promoted for the patented use or if the proposed label still encourages the patented method.

How did the Paragraph IV litigation begin?

Viatris submitted an ANDA seeking approval for a generic liraglutide injection. The ANDA included Paragraph IV certifications stating that the relevant Novo Nordisk patents were invalid, unenforceable or would not be infringed by the proposed product.

Novo Nordisk responded by filing suit under 35 U.S.C. § 271(e)(2). That provision treats the submission of an ANDA containing a Paragraph IV certification as an artificial act of patent infringement for purposes of resolving the dispute before generic launch.

The litigation triggers the Hatch-Waxman 30-month stay. The stay generally prevents FDA approval of the ANDA for up to 30 months from the date Novo Nordisk received Viatris’ Paragraph IV notice, unless the court orders an earlier termination or the case is resolved sooner.

What is the Orange Book status of Victoza?

Victoza’s Orange Book status is central to the case because Orange Book-listed patents determine the scope of the ANDA applicant’s certification obligations and can trigger the 30-month stay.

The Orange Book distinguishes between:

• Drug substance patents
• Drug product patents
• Method-of-use patents
• Patent expiration dates
• Pediatric exclusivity
• Patent delisting or expiration status

Victoza’s listed patents do not all have the same practical value. An expired foundational patent does not necessarily eliminate the commercial value of later formulation or use patents. The generic applicant can obtain approval after satisfying FDA requirements, but launch remains exposed to any enforceable patent that covers the product or its labeled use.

When does liraglutide lose exclusivity?

Liraglutide does not have a single exclusivity-loss date. The relevant dates depend on the patent, pediatric extension, regulatory exclusivity and the scope of the generic label.

Exclusivity category	Commercial significance
Foundational compound patent	Protects the active molecule and usually has the broadest scope
Formulation patent	Can restrict a particular concentration, excipient system or dosage form
Device patent	May affect pen-based or cartridge-based products
Method-of-use patent	Can restrict labeled treatment uses
FDA regulatory exclusivity	May delay approval independent of patent status
Pediatric exclusivity	Can extend eligible patent terms by six months

For Victoza, the principal generic-entry issue is whether the remaining enforceable patent claims cover Viatris’ proposed liraglutide injection and whether those claims survive invalidity and noninfringement challenges.

What legal issues are presented in the case?

The main issues in a case of this type are:

Infringement

Novo Nordisk must establish that Viatris’ proposed ANDA product or its proposed labeling would infringe one or more asserted claims. The court generally analyzes the product described in the ANDA, not an independently developed commercial product.

Patent validity

Viatris can challenge the asserted claims for:

• Anticipation
• Obviousness
• Lack of written description
• Lack of enablement
• Indefiniteness
• Double patenting
• Failure to satisfy statutory requirements

Obviousness is often the principal defense in pharmaceutical patent cases involving later formulations and therapeutic methods.

Patent enforceability

Viatris may assert inequitable conduct if it alleges that Novo Nordisk withheld material information from the U.S. Patent and Trademark Office with intent to deceive. This is a demanding defense requiring proof of materiality and specific intent.

Claim construction

The parties may dispute the meaning of terms relating to formulation composition, concentration, dosing frequency, therapeutic effect and product stability. Claim construction can determine whether the patent reaches the proposed generic product without requiring a full infringement trial.

Which companies are challenging Novo Nordisk’s liraglutide patents?

Viatris is one of several companies pursuing or evaluating generic GLP-1 products. The competitive field includes established generic manufacturers and specialty pharmaceutical companies with experience in injectable products.

A successful generic entrant must overcome more than the active-ingredient patent. It must also address:

• FDA quality requirements for an injectable product
• Device and pen compatibility
• Manufacturing scale
• Stability and storage requirements
• Pharmacokinetic or clinical requirements
• Patent claims covering formulation or delivery systems
• Supply-chain qualification and launch inventory

The technical burden is higher for an injectable GLP-1 product than for a conventional oral tablet.

What manufacturing and intellectual-property barriers affect generic liraglutide?

Liraglutide is a peptide product. Manufacturing requires controlled peptide synthesis, purification, formulation and sterile filling. A generic manufacturer must demonstrate consistent product quality and a reliable supply of finished dosage forms.

The principal manufacturing barriers are:

1. Peptide synthesis and impurity control
2. Maintaining product stability during storage
3. Sterile manufacturing capacity
4. Reproducible delivery through a multidose pen
5. Scale-up without changes in critical quality attributes
6. Compliance with FDA manufacturing controls

These barriers can delay market entry even when patent litigation is resolved. Injectable GLP-1 products also require more complex commercial infrastructure than standard small-molecule tablets.

What is the litigation status of Novo Nordisk v. Viatris?

The case was filed in January 2023 in the District of Delaware. Its procedural significance is the assertion of Novo Nordisk’s Victoza-related patent rights against Viatris’ ANDA.

The key litigation milestones are:

Date or event	Significance
January 2023	Novo Nordisk filed the complaint
2023	Viatris’ ANDA-based patent defenses became the central dispute
Litigation period	Discovery, claim construction and invalidity preparation governed the case
Potential resolution	Settlement, dismissal, judgment or consent order would determine the practical launch date
FDA approval	Separate from patent resolution and subject to any applicable stay

A docket-level determination of current trial, settlement or dismissal status is required before assigning a definitive launch date. The existence of an ANDA approval or regulatory filing does not by itself establish that Viatris may lawfully launch.

How strong is Novo Nordisk’s patent estate against Viatris?

Novo Nordisk’s position is strongest where the asserted claims cover the specific liraglutide formulation or delivery configuration described in Viatris’ ANDA and where the patent has a substantial remaining term.

The estate is weaker where:

• The asserted patent is close to expiration
• The claims depend on narrow formulation limitations
• Prior art discloses similar GLP-1 formulations
• Viatris can use a noninfringing formulation
• The generic label omits the patented indication
• The patent claims are vulnerable to obviousness or enablement attacks

The commercial value of the case therefore depends less on the number of listed patents than on the number of valid, enforceable claims that block a commercially viable generic product.

What generic launch scenarios exist for Victoza?

Three launch scenarios are commercially plausible.

Launch after patent expiration

Viatris could launch after the applicable patents expire, subject to FDA approval and manufacturing readiness. This is the lowest litigation-risk scenario.

Launch after settlement

Novo Nordisk and Viatris could agree to a negotiated entry date. A settlement may permit an earlier launch than the latest patent expiration while preserving Novo Nordisk’s remaining commercial protection.

Launch after successful invalidity or noninfringement ruling

Viatris could launch before patent expiration if it obtains a favorable judgment, secures dismissal of the asserted claims or otherwise eliminates the enforceable patent barrier.

A generic launch would likely pressure Victoza pricing and market share. The effect on Novo Nordisk would depend on the timing of entry, the number of approved competitors and continued demand for Saxenda, Ozempic, Wegovy and other GLP-1 products.

How does Victoza patent risk compare with Ozempic and Wegovy?

Product	Active ingredient	Primary patent-risk profile
Victoza	Liraglutide	Mature estate with compound, formulation and use patents
Saxenda	Liraglutide	Same active ingredient but different obesity indication and dosing
Ozempic	Semaglutide	Later-generation product with longer-running formulation and use protection
Wegovy	Semaglutide	Obesity indication, higher commercial value and separate use-related exposure

A Victoza generic challenge does not establish that semaglutide products face equivalent entry risk. Semaglutide has different patents, formulations, manufacturing requirements and commercial indications.

What is the revenue exposure for Novo Nordisk?

Victoza is a mature product relative to Novo Nordisk’s semaglutide portfolio. Generic entry would reduce pricing and volume for the diabetes injection, but the larger financial exposure is likely to involve portfolio substitution and payer behavior.

Potential effects include:

• Lower Victoza net price
• Reduced prescription volume
• Payer preference for lower-cost liraglutide
• Pressure on Saxenda pricing
• Greater promotional focus on Ozempic and Wegovy
• Manufacturing reallocation across GLP-1 products

The commercial impact would be materially larger if a generic liraglutide product obtains broad labeling and multiple competitors enter within a short period.

Key Takeaways

• Novo Nordisk v. Viatris, No. 1:23-cv-00013, is a Delaware Hatch-Waxman case involving generic liraglutide injection.
• The reference product is Victoza, not Ozempic or Wegovy.
• The case centers on Paragraph IV challenges to Novo Nordisk patents covering liraglutide-related products and uses.
• Patent risk depends on the surviving claims, not the total number of Orange Book listings.
• Formulation, device and method-of-use patents can delay generic entry after foundational compound protection expires.
• Viatris must overcome both patent barriers and the manufacturing complexity of a peptide injection.
• A final launch date depends on litigation resolution, patent expiration, FDA approval and any settlement restrictions.

FAQs About Novo Nordisk v. Viatris

Is Viatris seeking approval for generic Victoza?

Yes. The case concerns Viatris’ ANDA for a proposed generic liraglutide injection corresponding to Novo Nordisk’s Victoza product.

Does the case affect generic Ozempic?

No. Ozempic contains semaglutide, while Victoza contains liraglutide. The patents and FDA approval pathway are different.

Can Viatris launch before all Victoza patents expire?

Only if it obtains a favorable litigation outcome, reaches a settlement allowing entry, or otherwise avoids enforceable patents covering its proposed product and labeling.

Are liraglutide and semaglutide patent risks interchangeable?

No. They are different peptide molecules with different formulations, patents, manufacturing processes and approved indications.

Does FDA approval mean Viatris can immediately sell generic liraglutide?

No. FDA approval and patent clearance are separate requirements. An approved ANDA can remain subject to patent-based launch restrictions.

References

1. U.S. District Court for the District of Delaware. (2023). Novo Nordisk Inc. v. Viatris Inc., No. 1:23-cv-00013.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov

3. U.S. Food and Drug Administration. (2023). Victoza (liraglutide) prescribing information. https://www.accessdata.fda.gov

4. U.S. Code. (2023). 21 U.S.C. § 355(j).

5. U.S. Code. (2023). 35 U.S.C. § 271(e)(2).